Real-World Data and Real-World Evidence: Current status in the APAC region (Focus: Malaysia)
Our senior analyst Shimi Manayath Panakkal discussed about the usage of Real-World Data and Real-World Evidence in Malaysia with Dr. Sattian Kollanthavelu from Hospital Selayang, Malaysia. This is our fourth post in our interview series on Real-World Data.
. . . will help in understanding the overall trends in terms of disease burden and help in allocating funds accordingly
Lung Cancer – A Basic Understanding (Focus: Malaysia)
Cancer awareness is a continuous exercise that requires a multi-dimensional approach and proactive involvement of every stakeholder. Oncofocus, being a management consulting and research firm, will be publishing every month a short interview with leading Oncologists across the APAC region on a particular Cancer type. The main objective of these interviews is to learn the "What, Why, How" of the present state of cancer management directly from the treaters.
As August 01 is marked as the World Lung Cancer Day, our analyst Ms. Rihana Kuniyilakath connected with Dr. Vaishnavi Jeyasingam, clinical oncologist from Hospital Kuala Lumpur, a government tertiary referral hospital, that serves as a flagship hospital of the Malaysian public healthcare system
... newer drugs like osimertinib, alectinib, crizotinib etc. are also available ... Some of these molecular therapies have exorbitant prices and are beyond the reach of average citizens.
Real-World Data and Real-World Evidence: Current status in the APAC region
In the third interview of our the Real-World Data series, our analyst Shilna Kunnath connected with Dr. Randeep Singh, Director Medical Oncologist, Narayana Hospitals and Oncomed Clinic, Delhi/NCR to discuss about the current status of Real-world Data usage in India.
... real-world data is helpful in clinical evaluation of rare diseases where conducting regular controlled trials is not feasible.
Real-World Data and Real-World Evidence: Current status in the APAC region (Focus: Singapore)
In the second post of the interview series, our team members, Raja Mukesh Dokala, Senior Manager and Khusnuma Begum, Senior Analyst discussed the current status of RWD in Singapore with Prof Teo Eng Kiong, HoD, Department of Gastroenterology andChairman, Medical Board, Changi General Hospital, Singapore.
Real world data is essential because it reflects what really happens! It also helps us track how many patients cannot afford it (an expensive therapy) and what percent actually gets successfully treated.
Real-World Data and Real-World Evidence: Current status in the APAC region (Focus: Australia)
The use of real-world data (RWD) to supplement randomized clinical trials has been a growing trend recently. Several companies started using RWD to make informed pricing and reimbursement decisions and are also exploring other ways to use RWD in developing their clinical pipeline. At the same time, several countries are deliberating on how to employ real-world evidence (RWE) in their drug approval process.
... Australia or anywhere else the biggest problem now is noise in the data.